Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Verzenio (abemaciclib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly

Drug class:

CDK4/6 inhibitor

Related drugs:

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2
ER positive	Endometrial Cancer	ER positive	Endometrial Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
No biomarker	Breast Cancer	No biomarker	Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G13C	Non Small Cell Lung Cancer	KRAS G13C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B
Low NLR	Breast Cancer	Low NLR	Breast Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
High ALC	Breast Cancer	High ALC	Breast Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib + eFT226 Sensitive: B - Late Trials abemaciclib + eFT226 Sensitive : B	abemaciclib + eFT226 Sensitive: B - Late Trials abemaciclib + eFT226 Sensitive : B